Patents by Inventor John C. Cambier

John C. Cambier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220145253
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 12, 2022
    Applicants: NATIONAL JEWISH HEALTH, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
  • Publication number: 20210355214
    Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Applicant: Nepenthe Bioscience LLC
    Inventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
  • Patent number: 11078276
    Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: August 3, 2021
    Assignee: Nepenthe Bioscience LLC
    Inventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
  • Publication number: 20200308545
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
  • Patent number: 10760055
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 1, 2020
    Assignees: NATIONAL JEWISH HEALTH, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Publication number: 20200109198
    Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 9, 2020
    Applicant: Nepenthe Bioscience LLC
    Inventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
  • Publication number: 20190024051
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 24, 2019
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
  • Patent number: 9796961
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: October 24, 2017
    Assignees: The Regents of the University of Colorado, National Jewish Health
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Publication number: 20160040129
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: October 2, 2015
    Publication date: February 11, 2016
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
  • Patent number: 9150831
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: October 6, 2015
    Assignees: The Regents of the University of Colorado, National Jewish Health
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Publication number: 20150240205
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: October 8, 2014
    Publication date: August 27, 2015
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
  • Patent number: 8883507
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: November 11, 2014
    Assignees: The Regents of the University of Colorado, National Jewish Health
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Publication number: 20120148566
    Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
    Type: Application
    Filed: January 13, 2012
    Publication date: June 14, 2012
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Barbara J. Vilen, John C. Cambier
  • Publication number: 20110212111
    Abstract: The present invention provides a MHC II associated protein, MPYS, and methods for using the same. In particular, the MHC II-associated protein of the present invention mediates apoptosis and influences the susceptibility to infectious diseases. The present invention also provides methods for treating clinical conditions, methods for identifying therapeutically useful compounds using such a protein, and methods for determining susceptibility to infectious disease.
    Type: Application
    Filed: November 2, 2009
    Publication date: September 1, 2011
    Inventors: John C. Cambier, Lei Jin
  • Publication number: 20110097327
    Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
    Type: Application
    Filed: September 16, 2010
    Publication date: April 28, 2011
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Barbara J. Vilen, John C. Cambier
  • Publication number: 20100297763
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: February 5, 2010
    Publication date: November 25, 2010
    Applicant: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Patent number: 7825224
    Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: November 2, 2010
    Assignee: National Jewish Health
    Inventors: Barbara J. Vilen, John C. Cambier
  • Publication number: 20030077284
    Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
    Type: Application
    Filed: August 13, 2002
    Publication date: April 24, 2003
    Applicant: National Jewish Medical and Research Center
    Inventors: Barbara J. Vilen, John C. Cambier
  • Patent number: 6503509
    Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: January 7, 2003
    Assignee: National Jewish Medical & Research Center
    Inventors: Barbara J. Vilen, John C. Cambier